SANTONI, Natália; MELO, Thaís; AGUIRRE, Anna Rita; VEIGA, Daniela; SOUZA, Camila. Cost-effectiveness of afatinib versus pemetrexed plus cisplatin, erlotinib and gefitinib as first line treatment in patients with locally advanced or metastatic epidermal growth factor receptor mutation (EFGR+) non-small cell lung cancer in the Brazil. Jornal Brasileiro de Economia da Saúde, [S. l.], v. 9, n. 1, p. 73–82, 2017. DOI: 10.21115/JBES.v9.n1.p73-82. Disponível em: https://jbes.com.br/index.php/jbes/article/view/295. Acesso em: 28 abr. 2026.